Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer



Status:Recruiting
Conditions:Ovarian Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:February 5, 2016

Use our guide to learn which trials are right for you!

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when
given together or separately, and compares them to standard chemotherapy in treating patients
with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving
chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while
being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate
and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth.
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether giving cediranib maleate and olaparib together may cause more damage
to cancer cells when compared to either drug alone or standard chemotherapy.

PRIMARY OBJECTIVES:

I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib
maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice
standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting
of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube
cancer. (Phase II) II. To assess the efficacy of the combination of cediranib and olaparib,
and cediranib monotherapy, as measured by overall survival (OS) and PFS, as compared to
physician's choice standard of care chemotherapy in women with recurrent platinum-resistant
or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

SECONDARY OBJECTIVES:

I. To assess the efficacy of the combination of cediranib and olaparib, cediranib alone,
olaparib alone, and physician's choice standard of care chemotherapy, as measured by
objective response rate (ORR: partial or complete response) by Response Evaluation Criteria
in Solid Tumors (RECIST) 1.1 criteria, in the setting of recurrent platinum-resistant
or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II and Phase III)
II. To assess safety endpoints, as measured by frequency and severity of adverse events by
Common Terminology Criteria for Adverse Events (CTCAE). (Phase II and Phase III) III. To
assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy,
as measured by ORR as compared to physician's choice standard of care chemotherapy in the
setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or
fallopian tube cancer. (Phase III)

OBJECTIVES WITH INTEGRATED BIOMARKERS:

I. To assess correlation of homologous recombination deficiency (HRD) status, as assessed via
BROCA-HR assay with response, as measured by PFS and ORR. (Phase II) II. To evaluate the
prognostic and predictive role of circulating endothelial cells (CEC) on comparative
effectiveness of targeted therapies and reference chemotherapy. (Phase II) III. To evaluate
quality of life data compliance, as measured by the 9-item Disease Related Symptoms (DRS-9)
subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer
Therapy (FACT) Ovarian Symptom Index (NFOSI) for utilization and analysis in the Phase III
study. (Phase II) IV. To assess correlation of HRD status, as assessed via BROCA-HR assay
with response, as measured by OS, PFS and ORR. (Phase III) V. To evaluate the prognostic and
predictive role of circulating endothelial cells (CEC) on comparative effectiveness of
targeted therapies and reference chemotherapy. (Phase III) VI. To assess the effect on
disease-related symptoms (DRS) as measured by the 9-item DRS-P subscale of the NCCN-FACT
Ovarian Symptom Index-18 (NFOSI-18), of single agent cediranib and cediranib/olaparib
combination, compared to standard chemotherapy, in the setting of recurrent
platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase
III)

EXPLORATORY OBJECTIVES:

I. To assess exploratory biomarkers of potential HRD, including genomic scarring, BRCA1
methylation, BRCA1 protein expression, and mutations in NHEJ, and other genes that might
modify HRD. (Phase II and Phase III) II. To evaluate the prognostic and predictive role of
angiogenic biomarkers, as assessed by the Duke plasma angiome. (Phase II and Phase III) III.
To assess the effect on secondary measures of quality of life, as assessed by the treatment
side effects (TSE) and function/well-being (F/WB) subscales of the NFOSI-18, sensory
neuropathy as measured by the FACT/GOG-Ntx-4, and health utility as measured by the EQ-5D, of
single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy,
in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or
fallopian tube cancer. (Phase III)

OUTLINE:

PHASE II: Patients are randomized to 1 of 4 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice of standard of care
chemotherapy, comprising either paclitaxel intravenously (IV) on days 1, 8, 15, and 22 every
28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV on day 1 every 28 days
(Regimen II); or topotecan hydrochloride IV on days 1, 8, and 15 every 28 days or days 1-5
every 21 days (Regimen III). Treatment continues in the absence of disease progression or
unacceptable toxicity. No modification of the assigned regimens, such as additional drugs
(gemcitabine, or bevacizumab) is allowed. (12/05/2016)

ARM II (CEDIRANIB MALEATE AND OLAPARIB): Patients receive cediranib maleate orally (PO) and
olaparib PO as determined from an ongoing Phase I study. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.

ARM III (CEDIRANIB): Patients receive cediranib maleate PO daily continuously. Courses repeat
every 28 days in the absence of disease progression or unacceptable toxicity.

ARM IV (OLAPARIB): Patients receive olaparib PO twice daily (BID) on days 1-28. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity. (In July
2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).

PHASE III: Patients are randomized to 1 of 3 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice standard of care chemotherapy
as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs
(gemcitabine or bevacizumab) is allowed. (12/05/2016)

ARM II (CEDIRANIB AND OLAPARIB): Patients receive cediranib maleate PO and olaparib PO as in
Phase II Arm II.

ARM III (SINGLE AGENT): Patients receive cediranib maleate PO as determined by the Phase II
study. Courses repeat every 28 days in the absence of disease progression or unacceptable
toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for up to 3 years.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed ovarian cancer,
peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of
either serous or endometrioid cancer based on local histopathological findings; both
endometrioid and serous histology should be high-grade for eligibility of non-mutation
carriers; patients with clear cell, mixed epithelial, undifferentiated carcinoma, or
transitional cell carcinoma histologies are also eligible, provided that the patient
has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at
a clinical laboratory

- Note: Due to the long acceptance of BRCA testing through Myriad, Myriad testing
will be accepted; if testing for BRCA is done by other organizations,
documentation from a qualified medical professional (e.g., ovarian cancer
specialty physician involved in the field, high risk genetics physician, genetics
counselor) listing the mutation and confirming that the laboratory results showed
a recognized germ line deleterious BRCA 1 or BRCA 2 mutation or BRCA
rearrangement is required; a copy of Myriad or other BRCA mutational analysis
(positive or variants of unknown significance [VUS] or negative) reports will be
requested but not required for study enrollment

- Patients should have recurrent platinum-resistant or- refractory disease - defined as
disease that has progressed by imaging while receiving platinum or had recurrence
within 6 months of the last receipt of platinum-based chemotherapy; rising CA125 only
is not considered as platinum-resistant or refractory disease

- Phase II study: measurable disease by RECIST 1.1 criteria; if archival tumor sample is
not available tumor sample from fresh biopsy is acceptable

- Phase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR
non-measurable disease (defined as solid and/or cystic abnormalities on radiographic
imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or
pleural effusion that has been pathologically demonstrated to be disease-related in
the setting of a cancer antigen [CA]125 >= 2 x upper limit of normal [ULN])

- No more than 3 prior treatment regimens (including primary therapy; no more than 1
prior non-platinum based therapy in the platinum-resistant/-refractory setting);
hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will
not count towards this line limit

- Patients may not have had a prior anti-angiogenic agent in the recurrent setting;
prior use of bevacizumab in the upfront or upfront maintenance setting is allowed

- Patients may not have previously received a PARP-inhibitor

- Patient must have provided study specific informed consent prior to study entry

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 10 g/dL

- Total bilirubin within =< 1.5 times the upper limit of normal (ULN) institutional
limits

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 3 x institutional ULN; if intrahepatic liver metastases are present, AST and ALT
must be =< 5 times institutional ULN

- Creatinine =< 1.5 x the institutional ULN

- Urine protein: creatinine ratio urine protein creatinine (UPC) of =< 1 OR less than or
equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart;
UPC is the preferred test; patients with 2+ proteinuria on dipstick must also have a
24-hour urine collection demonstrating protein of =< 500 mg over 24 hours

- Toxicities of prior therapy (excepting alopecia) should be resolved to less than or
equal to grade 1 as per CTCAE

- Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic
blood pressure [DBP] =< 90 mmHg) on maximum of three antihypertensive medications;
patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical
professional within 2 weeks prior to starting study; it is strongly recommended that
patients who are on three antihypertensive medications must be actively followed by a
cardiologist or a primary care physician for management of BP while on protocol;
patients must be willing and able to check and record daily blood pressure readings;
blood pressure cuffs will be provided to patients randomized to cediranib alone and
the combination of olaparib and cediranib arms

- Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and
thyroid-stimulating hormone (TSH) within normal limits

- Able to swallow and retain oral medications and without gastrointestinal (GI)
illnesses that would preclude absorption of cediranib or olaparib

- Cediranib has been shown to terminate fetal development in the rat, as expected for a
process dependent on VEGF signaling; for this reason, women of child-bearing potential
must have a negative pregnancy test prior to study entry; women of child-bearing
potential must agree to use two reliable forms of contraception (hormonal or barrier
method of birth control; abstinence) prior to study entry, for the duration of study
participation, and for 6 weeks after cediranib discontinuation; should a woman become
pregnant or suspect she is pregnant while participating in this study, she should
inform her treating physician immediately

- Olaparib adversely affects embryofetal survival and development in the rat; for this
reason, women of child-bearing potential must have a negative pregnancy test prior to
study entry; women of child-bearing potential must agree to use must agree to use two
reliable forms of contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry, for the duration of study participation, and for 3
months after the last dose of olaparib; should a woman become pregnant or suspect she
is pregnant while participating in this study, she should inform her treating
physician immediately

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) of starting treatment or those who have not recovered
from adverse events due to agents administered more than 4 weeks earlier; patients may
not have had hormonal therapy within 2 weeks prior to entering the study; patients
receiving raloxifene for bone health as per Food and Drug Administration (FDA)
indication may remain on raloxifene absent other drug interactions

- Any other investigational agents within the past 4 weeks

- Prior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the
recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib,
sorafenib, pazopanib, cediranib, nintedanib, and trebananib; bevacizumab used in the
upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly
diagnosed disease will be allowed

- Prior use of PARP-inhibitors

- CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
measurable or otherwise evaluable disease

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to starting cediranib

- Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel
obstruction within 3 months prior to starting study drugs

- History of intra-abdominal abscess within the past 3 months

- History of gastrointestinal perforation; patients with a history of abdominal fistula
will be considered eligible if the fistula was surgically repaired or has healed,
there has been no evidence of fistula for at least 6 months, and patient is deemed to
be at low risk of recurrent fistula

- Dependency on IV hydration or total parenteral nutrition (TPN)

- Any concomitant or prior invasive malignancies with the following curatively treated
exceptions:

- Treated limited stage basal cell or squamous cell carcinoma of the skin

- Carcinoma in situ of the breast or cervix

- Primary endometrial cancer meeting the following conditions: stage not greater
than IA, grade 1 or 2, no more than superficial myometrial invasion, without
vascular or lymphatic invasion; no poorly differentiated subtypes, including
papillary serous/serous, clear cell, or other Federation of Gynecology and
Obstetrics (FIGO) grade 3 lesions

- Prior cancer treated with a curative intent with no evidence of recurrent disease
5 years following diagnosis and judged by the investigator to be at low risk of
recurrence

- Patients with untreated brain metastases, spinal cord compression, or evidence of
symptomatic brain metastases or leptomeningeal disease as noted on computed tomography
(CT) or magnetic resonance imaging (MRI) scans should not be included on this study,
since neurologic dysfunction may confound the evaluation of neurologic and other
adverse events; patients with treated brain metastases and resolution of any
associated symptoms must demonstrate stable post-therapeutic imaging for at least 6
months following therapy prior to starting study drug

- Patients with any of the following:

- History of myocardial infarction within six months

- Unstable angina

- Resting electrocardiogram (ECG) with clinically significant abnormal findings

- New York Heart Association functional classification of III or IV

- If cardiac function assessment is clinically indicated or performed: left ventricular
ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if
threshold for normal not otherwise specified by institutional guidelines

- Patients with the following risk factors should have a baseline cardiac function
assessment:

- Prior treatment with anthracyclines

- Prior treatment with trastuzumab

- Prior central thoracic radiation therapy (RT), including RT to the heart

- History of myocardial infarction within 6 to 12 months (Patients with
history of myocardial infarction within 6 months are excluded from the
study)

- Prior history of impaired cardiac function

- History of stroke or transient ischemic attack within six months

- Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm
or aortic dissection)

- Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior
thromboembolic events is permitted

- Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia
(AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated

- No prior allogeneic bone marrow transplant or double umbilical cord blood
transplantation (dUBCT)

- Patients may not use any complementary or alternative medicines including natural
herbal products or folk remedies as they may interfere with the effectiveness of the
study treatments

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia (other than atrial fibrillation with controlled ventricular rate), or
psychiatric illness/social situations that would limit compliance with study
requirements

- Known human immunodeficiency virus (HIV)-positive individuals are ineligible because
of the potential for pharmacokinetic interactions with cediranib or olaparib; in
addition, these individuals are at increased risk of lethal infections when treated
with marrow-suppressive therapy

- Participants receiving any medications or substances that are strong inhibitors or
inducers of CYP3A4 are ineligible

- Strong inhibitors and inducers of UGT/PgP should be used with caution

- Pregnant women are excluded from this study because cediranib and olaparib are agents
with the potential for teratogenic or abortifacient effects; because there is an
unknown but potential risk of adverse events in nursing infants secondary to treatment
of the mother with cediranib and olaparib, breastfeeding should be discontinued if the
mother is treated with cediranib or olaparib; these potential risks may also apply to
other agents used in this study
We found this trial at
325
sites
Marinette, Wisconsin 54143
Principal Investigator: Elizabeth L. Dickson Michelson
Phone: 414-302-2304
?
mi
from
Marinette, WI
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Carolyn Y. Muller
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Joyce F. Liu
Phone: 412-339-5294
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Cheung Wong
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Linda R. Duska
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Kelly J. Wilkinson
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Kristin K. Zorn
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Sarah W. Gordon
Phone: 804-628-1939
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Richard G. Moore
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Benjamin B. Bridges
Phone: 208-381-3376
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Heidi J. Gray
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Heidi J. Gray
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: David C. Starks
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Joel I. Sorosky
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, New York 12208
Principal Investigator: Joyce N. Barlin
Phone: 518-458-1390
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Carolyn Y. Muller
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 412-339-5294
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: David Griffin
Phone: 864-512-4651
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: J. R. Liu
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Namita Khanna
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1968 Peachtree Rd NW
Atlanta, Georgia 30309
(404) 605-5000
Principal Investigator: Adam W. Nowlan
Phone: 404-425-7943
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Guilherme Henrique C. Cantuaria
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Namita Khanna
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Kian Behbakht
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Pallavi P. Kumar
Phone: 443-777-7364
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Paul Celano
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Deborah K. Armstrong
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: William R. Robinson
Phone: 225-767-0822
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Patricia S. Braly
Phone: 225-215-1353
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bel Air, Maryland 21014
Principal Investigator: Ashkan Bahrani
Phone: 443-643-3010
?
mi
from
Bel Air, MD
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Benjamin B. Bridges
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Maria C. Bell
Phone: 218-333-5000
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Cheung Wong
Phone: 802-225-5400
?
mi
from
Berlin, VT
Click here to add this to my saved trials
9000 Rockville Pike
Bethesda, Maryland 20892
301-496-2563
Principal Investigator: Jung-min Lee
Phone: 800-411-1222
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Nicholas P. Taylor
Phone: 412-339-5294
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Maria C. Bell
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Benjamin B. Bridges
Phone: 208-381-3376
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Joyce F. Liu
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
?
mi
from
Brewer, ME
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Nicole S. Nevadunsky
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Brooklyn, New York 11203
Principal Investigator: Ovadia Abulafia
Phone: 718-613-8324
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Rabbie K. Hanna
Phone: 412-339-5294
?
mi
from
Brownstown, MI
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Burlington, Vermont 05405
Principal Investigator: Cheung Wong
Phone: 802-656-4101
?
mi
from
Burlington, VT
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Elizabeth L. Dickson Michelson
Phone: 414-302-2304
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Rachel E. Lerner
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
Camden, New Jersey 08103
Principal Investigator: David P. Warshal
Phone: 856-325-6757
?
mi
from
Camden, NJ
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carmichael, California 95608
Principal Investigator: Delphine W. Ong
Phone: 916-556-3301
?
mi
from
Carmichael, CA
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Linda Van Le
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
Principal Investigator: Steven J. Jubelirer
Phone: 304-388-9944
?
mi
from
Charleston, WV
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
(312) 864-6000
Principal Investigator: Thomas E. Lad
Phone: 312-864-5204
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Summer B. Dewdney
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60657
Principal Investigator: Ira A. Oliff
Phone: 224-534-7580
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Shohreh Shahabi
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
12961 27th Ave
Chippewa Falls, Wisconsin 54729
715-738-3700
Principal Investigator: Anthony C. Evans
Phone: 800-782-8581
Marshfield Clinic - Chippewa Center The 15,000 square foot Lake Hallie Center provides urgent care...
?
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Thomas J. Herzog
Phone: 513-558-4553
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
Principal Investigator: Kimberly E. Resnick
Phone: 216-778-8526
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinton Township, Michigan 48038
Principal Investigator: Rabbie K. Hanna
Phone: 313-916-1784
?
mi
from
Clinton Township, MI
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Clive, IA
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
Principal Investigator: Kian Behbakht
Phone: 719-365-2406
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
1 Hospital Dr
Columbia, Missouri 65212
(573) 882-2100
Principal Investigator: Erin R. Tuller
Phone: 573-882-7440
University of Missouri-Ellis Fischel Ellis Fischel Cancer Center's team of physician specialists and other trained...
?
mi
from
Columbia, MO
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Floor Backes
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: Rachel E. Lerner
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
?
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Covington, Louisiana 70433
Principal Investigator: Patricia S. Braly
Phone: 412-339-5294
?
mi
from
Covington, LA
Click here to add this to my saved trials
5201 Harry Hines Blvd
Dallas, Texas 75235
(214) 590-8000
Principal Investigator: Jayanthi S. Lea
Phone: 214-590-5582
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Jayanthi S. Lea
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Radhika P. Gogoi
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
?
mi
from
Danville, PA
Click here to add this to my saved trials
405 W Grand Ave
Dayton, Ohio 45405
(937) 723-3200
Principal Investigator: Thomas J. Reid
Phone: 937-298-3399
Grandview Hospital You'll feel like part of our family when you visit Grandview Medical Center...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Decatur, IL
Click here to add this to my saved trials
Denver, Colorado 80205
Principal Investigator: Alexander Menter
Phone: 303-764-5056
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Des Moines, Iowa 50309
Principal Investigator: Robert J. Behrens
Phone: 515-282-2921
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Rabbie K. Hanna
Phone: 313-916-1784
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Robert T. Morris
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Angeles A. Secord
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
900 W. Clairemont Ave.
Eau Claire, Wisconsin 54701
715 839-3956
Principal Investigator: Anthony C. Evans
Phone: 715-389-4457
Marshfield Clinic Cancer Center at Sacred Heart Marshfield Clinic Cancer Care at Sacred Heart Hospital...
?
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Edgewood, Kentucky 41017
Principal Investigator: Kevin M. Schuler
Phone: 859-301-5473
?
mi
from
Edgewood, KY
Click here to add this to my saved trials